科伦博泰生物(06990.HK)近日宣布,其核心产品SKB264(Sac-TMT)用于一线治疗三阴性乳腺癌(TNBC)的新适应症上市申请,已正式获得中国国家药品监督管理局(NMPA)受理。
科伦博泰生物(06990.HK)近日宣布,其核心产品SKB264(Sac-TMT)用于一线治疗三阴性乳腺癌(TNBC)的新适应症上市申请,已正式获得中国国家药品监督管理局(NMPA)受理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.